Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s40618-025-02682-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A potential age-independent MASLD-related liver fibrosis index based on metabolic profiling.
Sci Rep
September 2025
Department of Chemical Science and Technology, University of Rome "Tor Vergata", 00133, Rome, Italy.
The burden of metabolic dysfunction-associated steatotic liver disease (MASLD) is of immediate concern, as its prevalence is increasing worldwide. MASLD often progresses to liver fibrosis, posing significant health risks. Age-independent, noninvasive tools to evaluate fibrosis are needed to improve diagnostic accuracy across all age groups.
View Article and Find Full Text PDFFrom "Traditional" to "Trained" Immunity: Exploring the Novel Frontiers of Immunopathogenesis in the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
Biomedicines
August 2025
Hepatogastroenterology Division, Department of Precision Medicine, University of Campania Luigi Vanvitelli, 80138 Naples, Italy.
Metabolic dysfunction-associated steatotic liver disease (MASLD) has emerged as the most prevalent chronic hepatopathy and a leading precursor of hepatocellular carcinoma (HCC) worldwide. Initially attributed to insulin resistance (IR)-driven metabolic imbalance, recent insights highlight a multifactorial pathogenesis involving oxidative stress (OS), chronic inflammation, and immune dysregulation. The hepatic accumulation of free fatty acids (FFAs) initiates mitochondrial dysfunction and excessive reactive oxygen species (ROS) production, culminating in lipotoxic intermediates and mitochondrial DNA damage.
View Article and Find Full Text PDFCorrelation Between Hepatic and Splenic Steatosis Assessed by Transient Elastography in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease.
Cureus
July 2025
Gastroenterology and Hepatology, Dr. Ziauddin Hospital, Karachi, PAK.
Objective Metabolic dysfunction-associated steatotic liver disease (MASLD) can rapidly progress to steatohepatitis, liver fibrosis, and hepatocellular carcinoma. However, it is a multisystem disease, and most of the MASLD-related morbidity and mortality is due to its extrahepatic complications. In light of the growing impact of MASLD on extrahepatic organs, we aimed to evaluate spleen fat deposition and compare it with liver fat deposition by vibration-controlled transient elastography using its attenuation parameter.
View Article and Find Full Text PDFScreening for MASLD and Advanced Fibrosis Among Patients With Obesity: A Cost-Effectiveness Analysis.
Obesity (Silver Spring)
August 2025
Department of Health Policy and Management, Tulane School of Public Health and Tropical Medicine, New Orleans, Louisiana, USA.
Objective: The study aimed to compare the cost-effectiveness of various strategies for screening for MASLD-related advanced hepatic fibrosis (fibrosis stage > 2) using the fibrosis-4 index (FIB-4) and liver stiffness measurement (LSM) by transient elastography (TE) in persons with obesity.
Methods: We created a decision-analytic model comparing three screening strategies: no screening, TE, and FIB-4 followed by TE. We used a Markov transition model to track liver state, with prevalence and transition probabilities specific to the population with obesity.
Prevalence and risk of metabolic dysfunction-associated steatotic liver disease in patients with sarcopenic obesity: a systematic review and meta-analysis.
Nutr Metab (Lond)
August 2025
The Third Unit, Department of Hepatology, Beijing Youan Hospital, Capital Medical University, Beijing, 100069, P. R. China.
Background: The coexistence of sarcopenia and obesity has been established as a pivotal factor driving the pathological progression of metabolic dysfunction-associated steatotic liver disease (MASLD). This study systematically evaluates the prevalence and risk of MASLD in patients with sarcopenic obesity (SO).
Method: A comprehensive literature search was conducted in PubMed, Cochrane Library, EMBASE, Web of Science and SCOPUS up to March 2025.